The Free Press, Mankato, MN

News Ticker

State, national news

April 19, 2013

Drug maker accused of paying rival generic maker

GlaxoSmithKline target of investigation

WASHINGTON —

GlaxoSmithKline has been accused of paying other drugs companies to slow down production of generic versions of its most profitable antidepressant drug, according to the Office of Fair Trading.

An investigation into GSK has been launched by the OFT into allegations the company abused its market dominance by agreeing so-called "pay for delay" agreements between 2001 and 2004 to protect the position of its drug Seroxat.

GSK admitted agreements were reached but said they did not lead to delays in the generic versions coming to market.

Ann Pope, senior director of services, infrastructure and public markets at the OFT, said: "The introduction of generic medicines can lead to strong competition on price, which can drive savings for the NHS, to the benefit of patients and, ultimately, taxpayers.

"It is therefore particularly important that the OFT fully investigates concerns that independent generic entry may have been delayed in this case."

GSK said it refuted the allegations, adding that two similar investigations by the EU had concluded there was no wrongdoing.

But the OFT appears determined to discover if Alpharma, Genetics UK and Norton Healthcare were paid by GSK to delay production.

In a statement, the regulator claimed: "The generic companies were each attempting to supply a generic paroxetine product in competition to GSK's branded paroxetine product, Seroxat. However, in each case, GSK challenged the generic companies with allegations that their products would infringe GSK's patents. To resolve these disputes, each of the generic companies concluded one or more agreements with GSK.

"The OFT's provisional view is that these agreements included substantial payments from GSK to the generic companies in return for their commitment to delay their plans to supply paroxetine independently."

Seroxat, which is still available on the NHS, was launched in the early 1990s and became one of the biggest-selling drugs in the world, overtaking Prozac.

However, the patent came to an end in 2004 and generic, cheaper versions flooded the market, hitting profits.

A spokesman for the pharmaceutical giant said: "GSK supports fair competition and we very strongly believe that we acted within the law, as the holder of valid patents for paroxetine, in entering the agreements under investigation. These arrangements actually resulted in generic versions of paroxetine entering the market before GSK's patents had expired."

A spokeswoman for Pfizer, owners of Alpharma, said: "We are reviewing the statement of objections as it relates to a business Alpharma divested years before its acquisition by King. Pfizer, which subsequently acquired King, did not have any knowledge about this agreement, which dates to 2002. We will fully co-operate with the Office of Fair Trading regarding this matter."

A spokesman for Norton Healthcare in the US said he was unaware of the allegations and would issue a statement shortly.

Generics UK was unavailable for comment.

 

1
Text Only | Photo Reprints
State, national news
  • Hypersonic jets, lasers future for Air Force researchers WRIGHT-PATTERSON AIR FORCE BASE, Ohio — Air Force hypersonic weapons and fighter jets with lasers could fly in the skies of the future. Air Force Research Laboratory researchers have made top priorities of hypersonics, directed-energy weapons and au

    April 16, 2014

  • Dress codes: Where should schools set limits? EVANSTON, Ill. (AP) — They're called leggings — popular fashion items that are tight-fitting pants to some, and glorified tights to others. Younger girls often wear them as pants with little fuss. But as those same girls approach middle school, legg

    April 16, 2014

  • On Vegas Strip, the Harmon tower set to fall -- with a whimper LAS VEGAS — One by one, the grand old dames of the Strip outlived their charms — the Dunes, Stardust and Aladdin — and down they came, thanks to some well-rigged dynamite, in a booming flash of bravado and showmanship that became this city’s staple —

    April 16, 2014

  • Man accused of abusing 2 girls in 'Maidens Group' MINNEAPOLIS (AP) — Authorities were searching Tuesday for a self-professed minister accused of sexually abusing at least two girls in a "Maidens Group" at his religious fellowship in rural Minnesota, where he told one victim she would remain a virgin

    April 15, 2014

  • Deputy shot, wounded in Norman County PERLEY, Minn. (AP) — Authorities say a 19-year-old man from Fertile is under arrest for shooting a sheriff's deputy during a traffic stop in northwestern Minnesota. The Minnesota Bureau of Criminal Apprehension says the Norman County deputy was wear

    April 15, 2014

  • Red River Valley touted as drone industry center THIEF RIVER FALLS (AP) — Dozens of representatives from agriculture, aviation and higher education are meeting in northwestern Minnesota to discuss ways to promote the region as a center for development of the aircraft industry which produces unmanne

    April 15, 2014

  • Balancing Act: The secret weapon behind work life balance We all struggle for work life balance, but most of us don’t realize that sometimes the path toward achieving might be something so simple. Some of the most successful people I know are sharing their secret weapon for remaining strong and finding bal

    April 15, 2014

  • Police: Suspected killers wore GPS devices ANAHEIM, Calif. (AP) — Two convicted sex offenders dutifully checked in with police every month and wore their GPS trackers around the clock — the rules of parole that are designed to tip off authorities if a freed felon backslides. Yet for at least

    April 15, 2014

  • More US consumers are seeking medical care, report shows A historic slowdown in U.S. health care spending in recent years may be drawing to a close. An industry report published this week and health care experts point to a steady rise in medical care being sought by consumers seeing specialists, getting m

    April 15, 2014

  • Man sentenced to 20 years in synthetic drug case FARGO, N.D. (AP) — One of 15 people to plead guilty in a synthetic drug conspiracy that resulted in the overdose deaths of two teenagers has been sentenced to 20 years in prison. Casey Rosen (row-ZEEN') pleaded guilty in January 2013 to conspiracy to

    April 14, 2014

Press-Plus Subscribe
Sign In
Featured Ads
AP Video